Published in Gastroenterology on February 01, 2004
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol (2009) 2.72
A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry (2013) 2.68
Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol (2015) 2.64
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut (2007) 2.53
Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut (2007) 1.62
Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther (2011) 1.52
The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study. Int J Colorectal Dis (2012) 1.48
Effect of follow-up endoscopy on the outcomes of patients with inflammatory bowel disease. Dig Dis Sci (2014) 1.48
Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr (2009) 1.44
Episodic retreatment versus scheduled maintenance therapy of crohn's disease with infliximab: not so far apart. Gastroenterology (2004) 1.43
Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int (2006) 1.36
A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol (2012) 1.22
Retracted Biologic targeting in the treatment of inflammatory bowel diseases. Biologics (2009) 1.20
Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol (2012) 1.15
The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol (2010) 1.12
Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol (2010) 1.09
Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol (2006) 1.06
Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol (2009) 1.06
Long-term clinical outcomes of korean patient with Crohn's disease following early use of infliximab. Intest Res (2014) 1.05
Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf) (2015) 1.04
Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis? Yonsei Med J (2016) 1.03
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut (2007) 1.00
Biologics in inflammatory bowel disease: how much progress have we made? Gut (2004) 0.99
Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol (2011) 0.99
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis (2013) 0.98
Retinoic acid attenuates ileitis by restoring the balance between T-helper 17 and T regulatory cells. Gastroenterology (2011) 0.97
Tumour necrosis factor-alpha blockade suppresses murine allergic airways inflammation. Clin Exp Immunol (2007) 0.95
Racial disparities in utilization of specialist care and medications in inflammatory bowel disease. Am J Gastroenterol (2010) 0.92
Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy. World J Gastroenterol (2014) 0.92
Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol (2007) 0.91
Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol (2012) 0.91
Certolizumab pegol for the treatment of Crohn's disease. Therap Adv Gastroenterol (2011) 0.91
Infliximab: Use in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2005) 0.91
Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis (2005) 0.91
The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol (2010) 0.90
The valuable role of endoscopy in inflammatory bowel disease. Diagn Ther Endosc (2012) 0.89
Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci (2007) 0.88
Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J (2015) 0.88
Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol (2010) 0.88
Optimal use of biologics in the management of Crohn's disease. Therap Adv Gastroenterol (2010) 0.87
Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient (2013) 0.87
Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol (2010) 0.86
Review of the safety and efficacy of ustekinumab. Therap Adv Gastroenterol (2010) 0.86
Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol (2009) 0.86
Immunomodulators for all patients with inflammatory bowel disease? Therap Adv Gastroenterol (2010) 0.85
Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol (2010) 0.85
Infliximab extends the duration until the first surgery in patients with Crohn's disease. Biomed Res Int (2013) 0.85
Psychiatric comorbidity in the treatment of patients with inflammatory bowel disease. World J Gastroenterol (2014) 0.84
Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors. Am J Ophthalmol (2015) 0.83
A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency. Gastroenterol Hepatol (N Y) (2007) 0.83
Cytokine induction of tumor necrosis factor receptor 2 is mediated by STAT3 in colon cancer cells. Mol Cancer Res (2011) 0.83
Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years. Clin Exp Gastroenterol (2011) 0.83
Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol (2013) 0.83
Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. Brain Behav Immun (2014) 0.82
Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn's disease. Patient Prefer Adherence (2012) 0.82
Second Korean guidelines for the management of Crohn's disease. Intest Res (2017) 0.82
Conventional therapy for Crohn's disease. World J Gastroenterol (2006) 0.82
Health care resource use and costs in Crohn's disease before and after infliximab therapy. Can J Gastroenterol (2011) 0.82
Efficacy and safety of adalimumab in Crohn's disease. Therap Adv Gastroenterol (2008) 0.82
Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut (2007) 0.82
Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci (2007) 0.81
Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics (2009) 0.81
Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy. World J Gastroenterol (2014) 0.80
Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J Gastroenterol (2008) 0.80
The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis. Therap Adv Gastroenterol (2016) 0.80
Adalimumab in Crohn's disease. Biologics (2007) 0.80
Immunomodulation does not alter histology in resected Crohn's disease. Tech Coloproctol (2009) 0.79
Selective improvement of tumor necrosis factor capture in a cytokine hemoadsorption device using immobilized anti-tumor necrosis factor. J Biomed Mater Res B Appl Biomater (2011) 0.79
Resection of a methicillin-resistant Staphylococcus aureus liver abscess in a patient with Crohn's disease under infliximab treatment: a case report. J Med Case Rep (2013) 0.79
Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS One (2014) 0.79
Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. Dig Dis Sci (2015) 0.78
Need for infliximab dose intensification in Crohn's disease and ulcerative colitis. World J Gastroenterol (2014) 0.78
Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol (2008) 0.78
Anti-inflammatory activity of bioaccessible fraction from Eryngium foetidum leaves. Biomed Res Int (2013) 0.78
Impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn's disease: a single-center paired case-control study. Surg Today (2013) 0.78
Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study. Can J Gastroenterol Hepatol (2015) 0.78
Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediators Inflamm (2015) 0.78
Down-regulation of human enteric antimicrobial peptides by NOD2 during differentiation of the paneth cell lineage. Sci Rep (2015) 0.78
Targeting mucosal healing in Crohn's disease. Gastroenterol Hepatol (N Y) (2011) 0.78
Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease. Surg Today (2015) 0.78
Infliximab in the treatment of Crohn's disease. Ther Clin Risk Manag (2007) 0.78
Circulating cytokines reflect mucosal inflammatory status in patients with Crohn's disease. Dig Dis Sci (2009) 0.77
Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease. Dig Dis Sci (2014) 0.77
What is the impact of age on adult patients with inflammatory bowel disease? Clujul Med (2013) 0.77
Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn's Disease: A Hospital-Based Cohort Study. Dig Dis Sci (2016) 0.77
Change in the treatment strategy for pediatric Crohn's disease. Korean J Pediatr (2010) 0.77
The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis. Paediatr Drugs (2015) 0.77
Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol (2008) 0.77
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol (2016) 0.76
The classics in perspective. Gut (2007) 0.76
Crohn's disease. BMJ Clin Evid (2011) 0.75
Infliximab: the evidence for its place in therapy in ulcerative colitis. Core Evid (2008) 0.75
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges. Oncologist (2016) 0.75
Response to Infliximab in Crohn's Disease: Genetic Analysis Supporting Expression Profile. Mediators Inflamm (2015) 0.75
Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol (2015) 0.75
Crohn's disease. BMJ Clin Evid (2007) 0.75
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature (2012) 16.13
Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet (2008) 15.51
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet (2006) 15.14
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Transcriptome and genome sequencing uncovers functional variation in humans. Nature (2013) 8.89
XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell (2008) 8.43
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med (2008) 7.79
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet (2008) 6.97
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet (2009) 6.21
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation (2008) 5.20
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (2008) 5.05
Correlation between genetic and geographic structure in Europe. Curr Biol (2008) 5.02
The NLR gene family: a standard nomenclature. Immunity (2008) 4.77
PopGen: population-based recruitment of patients and controls for the analysis of complex genotype-phenotype relationships. Community Genet (2006) 4.72
Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet (2009) 4.63
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet (2009) 4.38
Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet (2005) 4.23
The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology (2002) 4.20
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Sci U S A (2009) 4.02
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet (2008) 3.99
Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain (2009) 3.96
On the use of general control samples for genome-wide association studies: genetic matching highlights causal variants. Am J Hum Genet (2008) 3.95
Management of Crohn's disease in adults. Am J Gastroenterol (2009) 3.94
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Nod2 is essential for temporal development of intestinal microbial communities. Gut (2011) 3.69
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
Investigation of the fine structure of European populations with applications to disease association studies. Eur J Hum Genet (2008) 3.65
The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med (2004) 3.63
A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension (2009) 3.48
Genetic structure of Europeans: a view from the North-East. PLoS One (2009) 3.46
Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet (2010) 3.39
A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology (2007) 3.37
Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest (2005) 3.36
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology (2008) 3.36
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology (2006) 3.32
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology (2013) 3.28
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25